

Thomas Wiegel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7833393/publications.pdf>

Version: 2024-02-01

86
papers

13,486
citations

201674

27
h-index

62596

80
g-index

95
all docs

95
docs citations

95
times ranked

12335
citing authors

#	ARTICLE	IF	CITATIONS
1	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2017, 71, 618-629.	1.9	2,497
2	EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intentâ€”Update 2013. <i>European Urology</i> , 2014, 65, 124-137.	1.9	1,613
3	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancerâ€”2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2021, 79, 243-262.	1.9	1,545
4	EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2014, 65, 467-479.	1.9	1,304
5	EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. <i>European Urology</i> , 2011, 59, 61-71.	1.9	1,299
6	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 630-642.	1.9	1,215
7	Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95. <i>Journal of Clinical Oncology</i> , 2009, 27, 2924-2930.	1.6	779
8	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	1.9	488
9	Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96â€”02/AUO AP 09/95 Trial. <i>European Urology</i> , 2014, 66, 243-250.	1.9	354
10	Functional Outcomes and Complications Following Radiation Therapy for Prostate Cancer: A Critical Analysis of the Literature. <i>European Urology</i> , 2012, 61, 112-127.	1.9	224
11	Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2017, 72, 869-885.	1.9	182
12	Early Salvage Radiotherapy Following Radical Prostatectomy. <i>European Urology</i> , 2014, 65, 1034-1043.	1.9	171
13	Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis. <i>European Urology</i> , 2012, 62, 472-487.	1.9	157
14	Prostate cancer: ESMO Consensus Conference Guidelines 2012. <i>Annals of Oncology</i> , 2013, 24, 1141-1162.	1.2	137
15	Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. <i>European Urology Focus</i> , 2020, 6, 231-234.	3.1	131
16	Achieving an Undetectable PSA After Radiotherapy for Biochemical Progression After Radical Prostatectomy Is an Independent Predictor of Biochemical Outcomeâ€”Results of a Retrospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1009-1016.	0.8	127
17	Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2014, 66, 479-486.	1.9	121
18	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology</i> , 2016, 69, 728-733.	1.9	102

#	ARTICLE	IF	CITATIONS
19	Prostate-Specific Antigen Persistence After Radical Prostatectomy as a Predictive Factor of Clinical Relapse-Free Survival and Overall Survival: 10-Year Data of the ARO 96-02 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 288-294.	0.8	77
20	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. <i>European Urology</i> , 2017, 71, 886-893.	1.9	77
21	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 436-444.	1.9	60
22	Salvage radiotherapy after prostatectomy – What is the best time to treat?. <i>Radiotherapy and Oncology</i> , 2012, 103, 239-243.	0.6	56
23	Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. <i>Journal of Clinical Oncology</i> , 2021, 39, 2284-2293.	1.6	54
24	Phase 3 Study of Adjuvant Radiotherapy Versus Wait and See in pT3 Prostate Cancer: Impact of Pathology Review on Analysis. <i>European Urology</i> , 2013, 64, 193-198.	1.9	38
25	Dose Escalation for Patients with Decreasing PSA during Radiotherapy for Elevated PSA after Radical Prostatectomy Improves Biochemical Progression-Free Survival. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 467-472.	2.0	36
26	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. <i>European Urology</i> , 2018, 73, 512-518.	1.9	36
27	Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. <i>HemaSphere</i> , 2018, 2, e160.	2.7	33
28	Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival. <i>Acta Oncologica</i> , 2018, 57, 362-367.	1.8	28
29	The German S3 Guideline Prostate Cancer. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 531-534.	2.0	26
30	Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 619-626.	2.0	26
31	Adjuvant Radiotherapy after Radical Prostatectomy: Indications, Results and Side Effects. <i>Urologia Internationalis</i> , 2007, 78, 193-197.	1.3	24
32	Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 133-143.	4.4	23
33	Quality assessment in prostate cancer centers certified by the German Cancer Society. <i>World Journal of Urology</i> , 2016, 34, 665-672.	2.2	23
34	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 150-169.	5.4	23
35	Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 727-731.	2.0	22
36	A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2021, 80, 531-545.	1.9	21

#	ARTICLE	IF	CITATIONS
37	The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary NO prostate cancer. <i>BJU International</i> , 2019, 124, 785-791.	2.5	20
38	Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 692-699.	2.0	19
39	Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. <i>European Urology</i> , 2015, 67, 904-912.	1.9	18
40	Effect of early salvage radiotherapy at PSA ≤ 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 344-349.	3.9	17
41	Patterns and Predictors of Early Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiation Therapy in Men With pT3N0 Prostate Cancer: Implications for Multimodal Therapies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 960-967.	0.8	16
42	Risk and timing of biochemical recurrence in pT3aNO/Nx prostate cancer with positive surgical margin – A multicenter study. <i>Radiotherapy and Oncology</i> , 2015, 116, 119-124.	0.6	16
43	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in pT2, pNO Patients With a Comprehensive Tumor Control Probability Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 333-340.	0.8	16
44	The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival. <i>Radiotherapy and Oncology</i> , 2016, 118, 131-135.	0.6	16
45	Value of PET imaging for radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1-23.	2.0	16
46	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. <i>European Urology</i> , 2019, 76, 179-186.	1.9	15
47	First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.249029.	5.0	15
48	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. <i>European Urology</i> , 2019, 76, 443-449.	1.9	14
49	The role of radiotherapy in localised and locally advanced prostate cancer. <i>Asian Journal of Urology</i> , 2019, 6, 153-161.	1.2	14
50	Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results. <i>World Journal of Urology</i> , 2013, 31, 423-428.	2.2	13
51	Radiation Therapy of Para-Aortic Lymph Nodes in Cancer of the Uterine Cervix. <i>Acta Oncologica</i> , 1993, 32, 63-67.	1.8	12
52	Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer. <i>European Journal of Cancer</i> , 2009, 45, 148-157.	2.8	10
53	PREFEREnce-based Randomized Evaluation of Treatment Modalities in Low or Early Intermediate-risk Prostate Cancer. <i>European Urology</i> , 2015, 67, 1-2.	1.9	10
54	Interdisciplinary decision making in prostate cancer therapy – 5-years time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charit� Berlin. <i>BMC Medical Informatics and Decision Making</i> , 2013, 13, 83.	3.0	9

#	ARTICLE	IF	CITATIONS
55	Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 235-242.	2.5	9
56	Options for Curative Treatment of Localized Prostate Cancer. <i>Deutsches A&#x0308;rztblatt International</i> , 2021, 118, .	0.9	7
57	Changes of Radiation Treatment Concept Based on 68Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy. <i>Frontiers in Oncology</i> , 2021, 11, 665304.	2.8	7
58	Percutaneous radiotherapy for low-risk prostate cancer: options for 2007. <i>World Journal of Urology</i> , 2007, 25, 53-57.	2.2	6
59	Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer. <i>Radiotherapy and Oncology</i> , 2021, 154, 255-259.	0.6	6
60	Salvage Radiotherapy in Patients with Persisting Prostate-Specific Antigen after Radical Prostatectomy for Prostate Cancer. <i>Oncology</i> , 2003, 65, 18-23.	1.9	5
61	Postoperative Radiotherapy for Advanced Prostate Cancer. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 485-487.	2.0	5
62	Adjuvant radiotherapy or early salvage radiotherapy in pT3R0 or pT3R1 prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 360-365.	1.8	5
63	Radiotherapy in the management of prostate cancer after radical prostatectomy. <i>Future Oncology</i> , 2013, 9, 669-679.	2.4	5
64	Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 325-332.	2.0	5
65	A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa. <i>Frontiers in Oncology</i> , 2021, 11, 723536.	2.8	5
66	Adjuvant radiotherapy after radical prostatectomy. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 171-176.	2.2	4
67	Postoperative radiotherapy in prostate cancer. <i>Lancet, The</i> , 2021, 397, 1623.	13.7	3
68	Optimizing radiotherapy for intermediate-risk localized disease. <i>Nature Reviews Urology</i> , 2018, 15, 470-471.	3.8	2
69	Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial. <i>World Journal of Urology</i> , 2021, 39, 65-72.	2.2	2
70	Value of PET imaging for radiation therapy. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 326-343.	0.7	2
71	Radiotherapy and Prostate Cancer: Quo Vadis?. <i>European Urology Supplements</i> , 2010, 9, 394-400.	0.1	1
72	Letter to the Editor on: A. Siegmann et al. Dose Escalation for Patients with Decreasing PSA during Radiotherapy for Elevated PSA after Radical Prostatectomy Improves Biochemical ProgressionFree Survival. Results of a Retrospective Study. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 763-764.	2.0	1

#	ARTICLE	IF	CITATIONS
73	Postprostatectomy Radiotherapy for Patients with High-risk Features on Definitive Pathology: A Plea for Evidence-based Medicine. <i>European Urology</i> , 2015, 68, 775-776.	1.9	1
74	Re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. <i>Eur Urol</i> 2019;76:732-739. <i>European Urology</i> , 2020, 77, e60-e61.	1.9	1
75	Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1746-1746.	1.6	1
76	Re: Timing of Radiotherapy After Radical Prostatectomy (Radicals-RT): A Randomised, Controlled Phase 3 Trial. <i>European Urology</i> , 2021, 80, 117.	1.9	1
77	Timing of ADT in Radiotherapy of Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2315-2316.	1.6	1
78	Prostate. <i>Medical Radiology</i> , 2011, , 949-1025.	0.1	0
79	Randomized Trials for Adjuvant Radiotherapy. <i>Medical Radiology</i> , 2014, , 231-242.	0.1	0
80	Re: GaÃtan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? <i>Eur Urol</i> 2019;76:265-277. <i>European Urology</i> , 2019, 76, e148-e149.	1.9	0
81	Reply to Fabiana Gregucci, Roberta Carbonara, and Alba Fiorentino's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>Eur Urol</i> 2020;77:614-627. <i>European Urology</i> , 2020, 78, e116-e117.	1.9	0
82	Moving Beyond the Hazard Ratio to Personalized Therapy: Is it Prime Time?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 903-904.	0.8	0
83	Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1273-1274.	2.5	0
84	Postoperative Irradiation: Immediate or Early Delayed?. , 2012, , 173-189.		0
85	Postoperative Irradiation: Immediate or Early Delayed?. , 2017, , 231-250.		0
86	Prostatakarzinom: PREFERE-Studie - Eine Standortbestimmung. , 0, , .		0